Molecular Classification of Gastric and Esophageal Cancers

Similar documents
Unravelling the Molecular Taxonomies of Gastroesophageal Cancers

Gastric and GE Junction Cancer: Epidemiology and Clinical Presentation

Molecular Pathology of Gastric Cancer

An integrative approach to cancer precision medicine

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker

Medicina Personalizada de Precisión en el Abordaje del Cáncer Gástrico. Dra Desamparados Roda Pérez Hospital Clínico de Valencia Incliva, CIBERONC

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

Review (V1) - The Hallmarks of Cancer

Resectable locally advanced oesophagogastric cancer

New developments in pathogenesis, gastric cancer. Matthias Ebert. II. Medizinische Klinik Klinikum rechts der Isar TU München

Biology of cancer development in the GI tract

ChromHMM Tutorial. Jason Ernst Assistant Professor University of California, Los Angeles

Cover Page. The handle holds various files of this Leiden University dissertation.

Review (V1) - The Hallmarks of Cancer

Alternative splicing. Biosciences 741: Genomics Fall, 2013 Week 6

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose

PD-L1 and Immunotherapy of GI cancers: What do you need to know

Liposarcoma*Genome*Project*

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

MEETING SUMMARY ECC 2015, SEPTEMBER 25TH 29TH 2015 BY PROF. DR. HANS PRENEN, LEUVEN, BELGIUM. Cancers of the Upper GI Tract

SINGAPORE SCIENTISTS DISCOVER METABOLIC DRUG CAN TREAT TERMINAL WEIGHT LOSS IN CANCER PATIENTS

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

Barrett s Esophagus: Old Dog, New Tricks

Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change

SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.

Key words: undifferentiated carcinoma of the esophagus, immunohistochemical stain, treatment for undifferentiated carcinoma of the esophaqus

Gastrointestinal pathology 2018 lecture 2. Dr Heyam Awad FRCPath

Gastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath

User s Manual Version 1.0

Development of Carcinoma Pathways

MEDIA RELEASE FOR IMMEDIATE RELEASE 11 SEPTEMBER 2017

Enterprise Interest Nothing to declare

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI

Histones modifications and variants

Cancer immunity and immunotherapy. General principles

Biomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club

Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic

Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

SINGAPORE SCIENTISTS DISCOVER NEW PATHWAYS LEADING TO CANCER PROGRESSION

The Cancer Genome Atlas & International Cancer Genome Consortium

Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

IPATIMUP Translational Research Unit Matching IPATIMUP s Expertise with Company s Research/Clinical Strategy

Session 4 Rebecca Poulos

Stage 4 gastric adenocarcinoma icd 10

RCC with Sarcomatoid Dedifferentiation: New Insights. Jose A. Karam, MD, FACS Assistant Professor Department of Urology November 6, 2015

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Triple Negative Breast Cancer

Disclosure Information

Granulocyte-colony-stimulating factor producing esophageal squamous cell carcinoma: a report of 3 cases

3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships

Epstein-Barr virus driven promoter hypermethylated genes in gastric cancer

What s New in Pathology of Genitourinary Tumors. Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine

Nature Genetics: doi: /ng Supplementary Figure 1

The Epigenome Tools 2: ChIP-Seq and Data Analysis

Session 4 Rebecca Poulos

DOCTORAL THESIS SUMMARY

of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.

Index. Note: Page numbers of article titles are in boldface type.

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

CLINICAL EFFECTIVENESS

Raymond Auerbach PhD Candidate, Yale University Gerstein and Snyder Labs August 30, 2012

mirna Dr. S Hosseini-Asl

Should novel molecular therapies replace old knowledge of clinical tumor biology?

Review Article Long Noncoding RNA H19 in Digestive System Cancers: A Meta-Analysis of Its Association with Pathological Features

Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France

Chapter 9, Part 1: Biology of Cancer and Tumor Spread

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

Learning Objectives:

Session 6: Integration of epigenetic data. Peter J Park Department of Biomedical Informatics Harvard Medical School July 18-19, 2016

Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment

History. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management

A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.

PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER

EBV infection B cells and lymphomagenesis. Sridhar Chaganti

Disclosure. I have nothing to disclose

Moving molecular subtypes to the clinic in gastric cancer

Pathogenesis of Natural Killer / T-cell Lymphoma

Accessing and Using ENCODE Data Dr. Peggy J. Farnham

The silence of the genes: clinical applications of (colorectal) cancer epigenetics

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

Accepted Manuscript. Pancreatic Cancer Subtypes: Beyond Lumping and Splitting. Andrew J. Aguirre

Pathology of the indolent B-cell lymphomas Elias Campo

Supplementary Tables. Supplementary Figures

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR

Genomic Methods in Cancer Epigenetic Dysregulation

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

RALYL Hypermethylation: A Potential Diagnostic Marker of Esophageal Squamous Cell Carcinoma (ESCC) Junwei Liu, MD

Update on Hereditary Gastric Cancer. Dr. Savtaj Brar MD MSc Surgical Oncologist Assistant Professor of Surgery

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

Computer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015

Computational Analysis of UHT Sequences Histone modifications, CAGE, RNA-Seq

Molecular subtyping: how useful is it?

Daniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017

Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries

Transcription:

Molecular Classification of Gastric and Esophageal Cancers Patrick Tan, MD PhD Professor, Duke-NUS Medical School Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology and Research (A*STAR) ESMO Preceptorship Program Singapore, Nov 2017

Outline of Presentation 1) Classification of Gastric and Esophageal CA - Geographical Differences - Molecular Profiles 2) Examining the Tumor Microenvironment - Driver roles for the Tumor Stroma 3) Modulation of Tumor Immunity - Evasion of host immune surveillance

Gastric and Esophageal Cancers : Leading Causes of Cancer Incidence and Death 3rd 6th

Gastric Cancer Pathogenesis : Interplay Between Environmental and Host Factors Yeoh and Tan (2015) Gastroenterology Chia and Tan (2016) Annals of Oncology

Esophageal CAs are Divided into Adenocarcinomas (EACs) and Squamous Cell Carcinomas (ESCC) EAC Prevalence in Western Countries ESCC Prevalence in Eastern Countries Rubenstein and Shaheen (2015) Gastroenterology

Esophageal Adenocarcinomas (EACs) and Gastric Cancers Similarities and Differences Premalignant Lesions - Barrett s Esophagus and Intestinal Metaplasia Treatment Regimes - Often grouped in trials (esp GEJ tumors) - Similar targets (eg HER2) Carcinogens and Exposures - H. pylori and Acid/Bile reflux Histological Subtypes - Intestinal type GC - Diffuse/Schirrous Type GC

Gastric Cancer Four Genomic Subtypes (USA TCGA) A) Chromosomal Instability (CIN) B) Microsatellite Instability (MSI) C) Genome Stable (GS) D) Epstein-Barr Virus (EBV) USA TCGA (2014) Nature

ACRG Classification Based on Gene Expression Cristescu, Lee et al., (2015) Nature Medicine

EAC : Pre-Malignant Barret s Esophagus Exhibits a Surprising Number of Somatic Mutations Esophageal Adenocarcinomas (EACs) Exhibit Increased Copy Number Alterations Ross-Innes, Becq et al (2015) Nature Genetics Stachler, Taylor-Weiner et al., (2015) Nature Genetics

Discovery of Therapeutically Relevant EAC Subtypes Based on Mutation Signatures OES127 MFD Secrier, Li et al., (2016) Nature Genetics

Remarkable Similarity of Esophageal Adenocarcinoma to CIN-type GC USA TCGA (2017) Nature

ESCCs - a Distinct Molecular Entity ESCC Specific : NFE2L2/NRF2 FAT genes NOTCH1, SOX2 and TP63 scnas and others Epigenetic Heterogeneity in ESCC Song et al., (2014) Nature Gao et al (2014) Nature Genetics Lin et al (2014) Nature Genetics Hao et al., (2016) Nature Genetics USA TCGA (2017) Nature

Outline of Presentation 1) Classification of Gastric and Esophageal CA - Geographical Differences - Molecular Profiles 2) Examining the Tumor Microenvironment - Driver roles for the Tumor Stroma 3) Modulation of Tumor Immunity - Evasion of host immune surveillance

Molecular and Clinical Heterogeneity in Gastric Cancer (GC) Tay et al., (2003) Cancer Research Tay et al., Cancer Research (2003)

Human Cancers as Cellular Ecosystems Am J Physiol Cell Physiol (2011)

Cellular Heterogeneity in Gastric Cancer (GC) Intestinal Diffuse / Scirrhous Glandular Morphology Gastric Atrophy Well Differentiated Better Prognosis Several targetable genetic alterations (eg HER2) Little cell adhesion No atrophy Poorly Differentiated Worse Prognosis Few targetable genetic alterations ( GS tumors )

GC Molecular Heterogeneity Reflects Distinct Cell Programs and Populations

Tumor Stromal Proportion Predicts Prognosis (Gene Expression/Digital Pathology) Gene Expression Histopathology Wu et al., 2013 Gut

Diffuse-Type Gastric Tumors Exhibit Elevated CAF/Cancer Cell Interactions Takatsugu Ishimoto Hideo Baba Kumamoto University

Isolation of Paired Normal Fibroblasts (NFs) and Cancer Associated Fibroblasts (CAFs) from DGC Patients Surgically Resected Tissue Gastric Ca NF and CAF in vitro culture adherent dish Exome-seq Confirms Almost No Somatic Mutations (ie Not EMT-Cancer Cells ) CAFs

GC Movement is Enhanced by CAF Co-culture OCUM12 (GC) OCUM12+NFs OCUM-12+CAFs * Experiments Done on ECM

CAF Co-culture Enhances GC Lymph Node Metastasis in vivo (PDX)

RNA-Sequencing of Paired NFs and CAFs Reveals Consistent Activation of TGFb-Signaling Moving Velocity

RHBDF2/iRHOM2 is Upregulated in CAFs and required for CAF Motility

RHBDF2/iRHOM2 Encodes a Pseudoprotease that Mediates Activation of TACE/ADAM17 Canonical TGFb Pathway Huang and Chen, Cell and Bioscience, 2012

TACE/ADAM17 Regulates Cleavage and Nuclear Accumulation of TGFBR1 ICD in CAFs TAPI2; TACE inhibitor

RHBDF2/iRHOM2 Silencing Reduces TGFBR1 Cleavage, Nuclear Accumulation, and TGFb Target Gene Expression

Summary - Spatial Analysis Highlights Intimate CAF/Cancer Cell Interactions in Diffuse-Type GC - CAFs Promote Cancer Cell Migration and Metastasis in vitro and in vivo ( Tugboat Mechanism ) - Genomic Analysis of CAFs Highlights RHBDF2 as a Regulator of the TGFb-driven Metastatic Program - RHBDF2 Stimulates TGFBR1 Cleavage and ICD Nuclear Import (Non-canonical TGFb Signaling) - A Potential Role for TACE/ADAM17 Inhibitors in Treatment of Diffuse-Type GC Ishimoto et al., (2017) Gastroenterology

Outline of Presentation 1) Classification of Gastric and Esophageal CA - Geographical Differences - Molecular Profiles 2) Examining the Tumor Microenvironment - Driver roles for the Tumor Stroma 3) Modulation of Tumor Immunity - Evasion of host immune surveillance

Cancer Gene Expression is Controlled by Epigenomic Changes Padmanabhan, Ushijima and Tan (2017) Nature Reviews Gastro Hepat

Regulatory Elements can be Identified by Histone Modifications Example Modification H3K4Me1 H3K4Me3 H3K4Me2 H2A.Z H3K27Ac H3K27Me3 H3K36Me3 H3K9Me3 Regulatory Elements Enhancers Promoters Active Enhancers/ Promoters Inactive Enhancers/ Promoters Transcribed Regions Constitutively Repressed Genes Active Promoter Poised Promoter Inactive Promoter H3K4Me3 H3K27Me3

Gene Promoters : Critical Integrators of Regulatory Inputs Valen and Sandelin (2011) Trends in Genetics

>50% of Human Genes have Multiple Promoters Davuluri et al (2008) Trends in Genetics

Epigenomic Promoter Profiling Localizes Somatic Promoters 19 N/T pairs + 12 cell lines (H3K4me3, H3K27ac, H3K4me1) 23,000 Promoter Elements (H3K4me3 High, H3K4me1 Low) Unaltered Tumor-Specific Gain (Somatic Gain) Tumor-Specific Loss (Somatic Loss)

Somatic Promoters are Correlated with H3K27ac Activity and Frequently Map to Multi-Isoform Genes

18% of GC Somatic Promoters Comprise Alternative Promoters

MET Altered Signaling Shown by N-terminal Promoter Variants Muratani et al., 2014 Nat Comm TCGA (Papillary RCC) 2016 NEJM

Recurrent Alternative Promoters are Predicted to Cause Loss of N-terminal Immunogenic Peptides MHC Class I Binding (HLA A, B, C)

Recurrent N-terminal Peptides Stimulate Immune Responses in Experimental Systems

GCs with High Alternative Promoter Usage Exhibit Decreased T-Cell Cytolytic Activity (GZMA, PRF1)* * Adjusted for mutation count and tumor purity TCGA Nature 2014 (RNA-seq) ACRG Nat Med 2015 (Nanostring)

Model - Somatic Promoter Alterations in GC May Reflect the Impact of Tumor Immunoediting

Summary Largest catalogue of epigenome-guided promoter elements in gastric cancer Tumor-specific promoter alterations are widespread and frequently map to multi-isoform genes Alternative promoters can drive expression of novel pro-oncogenic isoforms (eg RASA3, MET) Alternative promoter usage may decrease tumor antigenicity (immunoediting) Somatic promoters exhibit heightened sensitivity to EZH2 perturbation Qamra et al., (2017) Cancer Discovery

Acknowledgements Takatsugu Ishimoto Hideo Baba Kumamoto University Aditi Qamra Manjie Xing Nisha Padmanabhan Jeffrey Kwok Shenli Zhang Chang Xu Yan Shan Leong Lee-Lim Ai Ping Qianqao Tang Keisuke Miyake Masakazu Yashiro Nobuyuki Onishi Daisuke Kuroda Kota Arima Daisuke Izumi Masaaki Iwatsuki Yoshifumi Baba Eiji Oki Masayuki Watanabe Kosei Hirakawa Hideyuki Saya John Connolly Kyoung Mee-Kim Jeeyun Lee Dennis Kappei Khay Guan Yeoh Tannistha Nandi Kie Kyon Huang Lin Suling Joyce Ramnarayanan Kalpana Su Ting Tay Yuka Suzuki Byoung Chul Cho Pierce Chow Wai Keong Wong Hock Soo Ong Khee Chee Soo Duane Smoot Hassan Ashktorab Sun Young Rha